QUOIN PHARMACEUTICALS, LTD. (QNRX)
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
📈 **POSITIVE** • Low confidence analysis (53%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (75%) **Content type:** Clinical